DIA Biosimilars 2013

Redwood Bioscience

Catalent Biologics expands into ADCs through license with Redwood Bioscience

Tuesday, April 16, 2013 10:34 AM

Catalent Pharma Solutions has acquired an exclusive license to market Redwood Bioscience's proprietary SMARTag precision protein-chemical engineering technology for the development of advanced antibody-drug conjugates (ADCs).

More... »

Cenduit: Now with Patient Reminders

Redwood Bioscience names executive chairman

Tuesday, October 4, 2011 10:53 AM

Redwood Bioscience has named Peter Van Vlasselaer, PhD, executive chairman to Redwood's board of directors.  In this role, Vlasselaer will be actively guiding Redwood on drug and platform development as well as corporate strategy.  

More... »

CRF Health – eCOA Forum

Redwood secures funding for drug development

Monday, July 11, 2011 12:46 PM

Redwood Bioscience has secured funding from Takeda Ventures to further develop its precision protein-chemical engineering platform for drug conjugate optimization.  This funding will be applied to advancing Redwood's site specific protein modification technology for enhancing antibody-drug conjugates and peptide therapeutics.  

More... »

CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs